The trial stands as a robust case study for methodological comparison, given its expansive scope examining oncogenic RET alterations across a diverse range of solid tumors, like Non-Small Cell Lung Cancer (NSCLC) and Medullary Thyroid Cancer (MTC), and other solid tumors. The gene discussed is RET; the disease is non-small cell lung carcinoma.